Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu.
Authors: Klimek L, Demoly P, Price D
Abstract
For any allergic rhinitis (AR) treatment, it is crucial to provide evidence not only of efficacy (assessed in randomized controlled trials (RCTs)) but also of effectiveness in real-life. Observational studies provide valuable data on the use and results associated with interventions prescribed in real-life. However, real-life evidence supporting available AR treatment options is sparse with effectiveness only established for oral antihistamines (desloratadine, ebastine), intranasal corticosteroids (mometasone furoate, fluticasone propionate (FP)), allergen immu...
Source: Expert Review of Clinical Pharmacology - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis.
Authors: Klimek L, Mullol J, Hellings P, Gevaert P, Mösges R, Fokkens W
Abstract
INTRODUCTION: Allergic rhinitis (AR) has a major negative impact on patients' quality of life (QoL) and carries a high socio-economic burden. This is particularly the case for patients who experience symptoms for extended periods of time (i.e. those with perennial (PAR) or persistent AR (PER), depending on the classification system used). This review covers available pharmacological advances and recent developments in the treatment of PAR or PER. Areas covered: Pharmacological AR treatment is used to reduce symptom burden and...
Source: Expert Opinion on Pharmacotherapy - February 14, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Involvement of mast cells and proteinase-activated receptor 2 in oxaliplatin-induced mechanical allodynia in mice
Publication date: Available online 21 January 2016 Source:Pharmacological Research Author(s): Ayumi Sakamoto, Tsugunobu Andoh, Yasushi Kuraishi The chemotherapeutic agent oxaliplatin induces neuropathic pain, a dose-limiting side effect, but the underlying mechanisms are not fully understood. Here, we show the potential involvement of cutaneous mast cells in oxaliplatin-induced mechanical allodynia in mice. A single intraperitoneal injection of oxaliplatin induced mechanical allodynia, which peaked on day 10 after injection. Oxaliplatin-induced mechanical allodynia was almost completely prevented by congenital ma...
Source: Pharmacological Research - January 25, 2016 Category: Drugs & Pharmacology Source Type: research
Effects of azelastine nasal spray on nasal and nasopharyngeal microflora.
CONCLUSION: The use of azelastine nasal spray for one month did not have a statistically significant effect on the numbers of nasal and nasopharyngeal microflora; it is therefore safe from a microbiological viewpoint.
PMID: 26515526 [PubMed - as supplied by publisher] (Source: Journal of Laryngology and Otology)
Source: Journal of Laryngology and Otology - November 1, 2015 Category: ENT & OMF Tags: J Laryngol Otol Source Type: research
Azelastine hydrochloride/fluticasone propionate combined in a single nasal spray: a guide to its use in allergic rhinitis
Abstract
Azelastine hydrochloride/fluticasone propionate 137/50 μg nasal spray (henceforth MP-AzeFlu) [Dymista®] provides a combination of two first-line treatments for allergic rhinitis, an intranasal antihistamine and an intranasal corticosteroid, in a single spray. In 14-day clinical trials in patients with allergic rhinitis, MP-AzeFlu improved nasal and ocular symptoms to a significantly greater extent than placebo or monotherapy with its individual active components (either marketed products or products re-formulated in the MP-AzeFlu formulation). MP-AzeFlu’s novel formulation contributes to its...
Source: Drugs and Therapy Perspectives - October 13, 2015 Category: Drugs & Pharmacology Source Type: research
Escaping the trap of allergic rhinitis
Rhinitis is often the first symptom of allergy but is frequently ignored and classified as a nuisance condition. Ironically it has the greatest socioeconomic burden worldwide caused by its impact on work and on daily life.However, patients appear reticent to seek professional advice, visiting their doctor only when symptoms become ‘intolerable’ and often when their usual therapy proves ineffective.Clearly, it’s time for new and more effective allergic rhinitis treatments.MP29-02 (Dymista®; Meda, Solna, Sweden) is a new class of medication for moderate to severe seasonal and perennial allergic rhinitis if monotherapy...
Source: Clinical and Molecular Allergy - August 4, 2015 Category: Allergy & Immunology Authors: Oliviero RossiIlaria MassaroMarco CaminatiCristina QuecchiaFilippo FassioEnrico HefflerGiorgio Canonica Source Type: research
H1‐antihistamines for primary mast cell activation syndromes: a systematic review
ConclusionsThere is an urgent need for large, well‐designed, double‐blind, placebo‐controlled randomized trials investigating the effectiveness, cost‐effectiveness, and safety of second‐generation H1‐antihistamines in treatment of primary MCAS. (Source: Allergy)
Source: Allergy - July 6, 2015 Category: Allergy & Immunology Authors: U. B. Nurmatov, E. Rhatigan, F. E. R. Simons, A. Sheikh Tags: Review Article Source Type: research
Neural Abnormalities in Nonallergic Rhinitis
Abstract
Sensory nerve endings within the airway epithelial cells and the solitary chemoreceptor cells, synapsing with sensory nerves, respond to airborne irritants. Transient receptor potential (TRP) channels (A1 and V1 subtypes, specifically) on these nerve endings initiate local antidromic reflexes resulting in the release of neuropeptides such as substance P and calcitonin G-related peptides. These neuropeptides dilate epithelial submucosal blood vessels and may therefore increase transudation across these vessels resulting in submucosal edema, congestion, and rhinitis. Altered expression or activit...
Source: Current Allergy and Asthma Reports - July 2, 2015 Category: Allergy & Immunology Source Type: research
Interactions between histamine H1 receptor and its antagonists by using cell membrane chromatography method
ConclusionsThe studies showed CMC could be applied to investigate drug–receptor interactions. (Source: Journal of Pharmacy and Pharmacology)
Source: Journal of Pharmacy and Pharmacology - July 1, 2015 Category: Drugs & Pharmacology Authors: Weina Ma, Dongdong Zhang, Jing Li, Delu Che, Rui Liu, Jie Zhang, Yanmin Zhang Tags: Research Paper Source Type: research
Intranasal spray medications for maintenance therapy of allergic rhinitis.
CONCLUSION: The most recent addition to intranasal sprays for the maintenance therapy of AR is MP-AzeFlu, a single formulation nasal spray of azelastine hydrochloride and fluticasone propionate in an advanced delivery system. Analysis of clinical data showed this to be the first new intranasal medication that provides greater clinical benefit than an INCS in treating AR.
PMID: 26132312 [PubMed - as supplied by publisher] (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - June 29, 2015 Category: ENT & OMF Authors: Berger WE, Meltzer EO Tags: Am J Rhinol Allergy Source Type: research
Intranasal spray medications for maintenance therapy of allergic rhinitis.
CONCLUSION: The most recent addition to intranasal sprays for the maintenance therapy of AR is MP-AzeFlu, a single formulation nasal spray of azelastine hydrochloride and fluticasone propionate in an advanced delivery system. Analysis of clinical data showed this to be the first new intranasal medication that provides greater clinical benefit than an INCS in treating AR.
PMID: 26103638 [PubMed - as supplied by publisher] (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - June 22, 2015 Category: ENT & OMF Authors: Berger WE, Meltzer EO Tags: Am J Rhinol Allergy Source Type: research
Clinical development of an advanced intranasal delivery system of azelastine hydrochloride and fluticasone propionate.
Authors: Derendorf H, Meltzer EO, Hermann R, Canonica GW
Abstract
There is no shortage of pharmacologic treatments available for the management of allergic rhinitis (AR), but none regularly provide full relief from all symptoms. MP29-02 (Dymista®) is a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), benefiting from an enhanced formulation and improved device characteristics compared to marketed intranasal corticosteroid (INS) formulations. Results from large, randomized, double-blind, placebo-controlled, head-to-head trials versus first-line therapies, confi...
Source: Drugs of Today - June 4, 2015 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis.
CONCLUSIONS: It seems that all reported topical antihistamines and mast cell stabilisers reduce symptoms and signs of seasonal allergic conjunctivitis when compared with placebo in the short term. However, there is no long-term data on their efficacy. Direct comparisons of different antihistamines and mast cell stabilisers need to be interpreted with caution. Overall, topical antihistamines and mast cell stabilisers appear to be safe and well tolerated. We observed a large variability in outcomes reported. Poor quality of reporting challenged the synthesis of evidence.
PMID: 26028608 [PubMed - as supplied by publis...
Source: Cochrane Database of Systematic Reviews - June 1, 2015 Category: Journals (General) Authors: Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A Tags: Cochrane Database Syst Rev Source Type: research
Design and validation of an HTRF(®) cell-based assay targeting the ligand-gated ion channel 5-HT3A.
We present a new Tag-lite(®) ligand-binding assay targeting LGICs on living cells. This technology combines the use of suicide enzyme tags fused to channels of interest with homogeneous time-resolved fluorescence (HTRF(®)) as the detection readout. Using the 5-HT3 receptor as system model, we showed that the pharmacology of the HALO-5HT3 receptor was identical to that of the native receptor. After validation of the assay by using 5-HT3 agonists and antagonists of reference, a pilot screen enabled us to identify azelastine, a well-known histamine H1 antagonist, as a potent 5-HT3 antagonist. This interesting result was con...
Source: Analytical Biochemistry - May 18, 2015 Category: Biochemistry Authors: Blanc E, Wagner P, Plaisier F, Schmitt M, Durroux T, Bourguignon JJ, Partiseti M, Dupuis E, Bihel F Tags: Anal Biochem Source Type: research
Health-care costs of asthma are lower using mp29-02* vs. Sequential sprays for allergic rhinitis
The objective was to examine healthcare costs related to AR and asthma for patients either treated with MP29-02*, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system, or combination therapy with single ingredient intranasal antihistamine (INA) and intranasal corticosteroid (INS) sprays. (Source: Value in Health)
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: B. Harrow, A.R. Sedaghat, U. Munzel, A. Tarr, L. Gever, J. Hofmeister, R. Dufour Source Type: research
